Clinical Trial

Target Attainment of Continuous Infusion Flucloxacillin and Cefazolin Coupled With TDM vs. Standard of Care Treatment in Patients With Complicated S. Aureus Infection

Study acronym: TARGET III

Recruiting Phase 2

Record status

This record was last updated December 16, 2024 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.

Summary

This prospective randomized, controlled interventional pilot trial, aims to compare the achievement of the optimal target concentration with continuously administered flucloxacillin (FLU) or cefazolin (CZO) coupled with TDM and subsequent dose adjustment versus standard of care (intermittent bolus application without TDM-guidance) in patients with complicated Staphylococcus aureus (S. aureus) infections (CSAI). The overall goal is to individualize and optimize antibiotic treatment in a very vulnerable group of patients overcoming the standard strategy of "one-dose-fits-all".

Protocol Amendment History 4 amendments

This ClinicalTrials.gov record has been amended 4 times since 2022-12-14; most recent amendment 2024-12-13.

Status change: Not Yet Recruiting → Recruiting 2023-10-25

Trial Details

NCT Number	NCT05655091
Lead Sponsor	University Hospital, Basel, Switzerland
Conditions	Complicated Staphylococcus Aureus (S. Aureus) Infections (CSAI)
Enrollment	36 participants
Start Date	2023-10-26
Primary Completion	2025-12 (estimated)
Study Completion	2025-12 (estimated)
Updated on ClinicalTrials.gov	2024-12-16